Journal article
Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer
Abstract
PURPOSE: ALK-targeted therapy with crizotinib offers significant improvement in clinical outcomes for the treatment of EML4-ALK fusion-positive non-small-cell lung cancer (NSCLC). We estimated the cost effectiveness of EML4-ALK fusion testing in combination with targeted first-line crizotinib treatment in Ontario.
PATIENTS AND METHODS: A cost-effectiveness analysis was conducted using a Markov model from the Canadian Public health (Ontario) …
Authors
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao M-S; Cutz J-C; Leighl NB
Journal
Journal of Clinical Oncology, Vol. 32, No. 10, pp. 1012–1019
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
April 1, 2014
DOI
10.1200/jco.2013.53.1186
ISSN
0732-183X